

Edgar Filing: Cellular Biomedicine Group, Inc. - Form 8-K

Cellular Biomedicine Group, Inc.  
Form 8-K  
March 16, 2018

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 16, 2018

CELLULAR BIOMEDICINE GROUP, INC.  
(Exact name of registrant as specified in its charter)

Delaware 001-36498 86-1032927  
(State or other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)

19925 Stevens Creek Blvd., Suite 100 95014  
Cupertino, California  
(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: (408) 973-7884

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 7.01 Regulation FD Disclosure.

Attached as Exhibit 99.1 to this Current Report is the form of presentation that Cellular Biomedicine Group, Inc. (the “Company”) used in connection with the Company’s presentation on March 16, 2018 at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium conference in Hangzhou, China, at which the Company presented 48-week clinical data from its Phase I clinical trial in China for allogeneic adipose-derived mesenchymal progenitor cell off-the-shelf therapy Allojoin™ for Knee Osteoarthritis.

On March 16, 2018, the Company issued a press release announcing the presentation of the Allojoin™ Phase I 48-week data in China, as well as the termination of the Company’s U.S. Allojoin™ program with the California Institute of Regenerative Medicine (“CIRM”). Prior to termination, the Company had received \$1.2 million of the potential \$2.29 million available under the CIRM grant. The press release is attached hereto as Exhibit 99.2.

The foregoing (including Exhibits 99.1 and 99.2) is being furnished pursuant to Item 7.01 and will not be deemed to be filed for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise be subject to the liabilities of that section, nor will it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

99.1 Presentation, dated March 16, 2018

99.2 Press Release, dated March 16, 2018



SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Cellular Biomedicine Group,  
Inc.

Date: March 16, 2018 By: /s/ Bizuo (Tony) Liu  
Bizuo (Tony) Liu  
Chief Executive Officer